Alternative splicing-based therapeutics for neurodegenerative diseases: a dual-database bibliometric and NLP-driven analysis (2000–2025) - Takeaways - MDSpire

Alternative splicing-based therapeutics for neurodegenerative diseases: a dual-database bibliometric and NLP-driven analysis (2000–2025)

  • By

  • De-Zhu Liu

  • Gao-Lu Cheng

  • Chen-Feng Hu

  • Ru-Yang Li

  • Cong-Chu Yang

  • Ning-Chuan Chen

  • Xiang Li

  • De-You Jiang

  • Jia-Yi Chang

  • June 16, 2026

  • 0 min

Share

  • 1

    Aberrant alternative splicing (AS) is a critical pathogenic mechanism in neurodegenerative diseases (NDDs).

  • 2

    The study utilized bibliometric and NLP methods to analyze global research trends in AS-targeted therapeutics for NDDs from 2000 to 2025.

  • 3

    Publication output on AS-based therapeutics showed sustained growth, with the US and Western Europe as leading research hubs.

  • 4

    LDA topic modeling identified three core axes: molecular mechanisms, disease-specific models, and translational methodologies.

  • 5

    The findings highlight the need to expand RNA-targeted therapies beyond pediatric disorders like spinal muscular atrophy into adult NDDs.

Original Source(s)

Alternative splicing-based therapeutics for neurodegenerative diseases: a dual-database bibliometric and NLP-driven analysis (2000–2025)

  • by De-Zhu Liu, Gao-Lu Cheng, Chen-Feng Hu, Ru-Yang Li, Cong-Chu Yang, Ning-Chuan Chen, Xiang Li, De-You Jiang, Jia-Yi Chang

  • June 16, 2026

Related Content

TNmindtest: Development and evaluation of a web-based cognitive screening tool for mild cognitive impairment in Vietnamese adults

‘Are we just going to give up and die like every other generation?’

This Week’s CGT News: CAR-T Breaks New Ground in Alzheimer’s

First CAR-T approach for Alzheimer’s reduces amyloid plaques in mice, while cell and gene therapies advance across blood cancers, retinal disease, amyloidosis, and FSHD

  • May 11, 2026

  • 7 min